<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85548">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01743950</url>
  </required_header>
  <id_info>
    <org_study_id>CO11374</org_study_id>
    <nct_id>NCT01743950</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of Pulse Reduced Dose Rate (PRDR) radiation when given in 27
      fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until
      time of progression in patients with recurrent high grade gliomas (grade III and grade IV).
      Patients will be placed in 1 of 4 groups based on their histologic diagnosis and prior
      exposure to bevacizumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>end of study, which will be an average of 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>time of first dose of PDRD+ Bevacizumab until time of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety profile</measure>
    <time_frame>assessed  every two weeks prior to each bevacizumab infusion while on treatment then 30 post completion of therapy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>time of first dose of PDRD+ Bevacizumab until time of death. All changes from baseline assessment will be recorded until 30 days post last dose of bevacizumab. In addition any late toxicity that is likely attributable to re-irradiation or bevacizumab will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>at 3months for bevacizumab exposed patients, at 6 and 12 months for all patients</time_frame>
    <safety_issue>No</safety_issue>
    <description>will be determined based on clinical and radiographic evidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurologic changes</measure>
    <time_frame>baseline and then approximately every 8 weeks for 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>will be assessed by physician with mini-mental exam and a FACT BR completed by the patient</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Bevacizumab naive recurrent grade IV gliomas</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacuzumab exposed and refractive grade IV gliomas</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab naive recurrent grade III gliomas</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab exposed and refractive grade III gliomas</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10mg/kg every 2weeks.</description>
    <arm_group_label>Bevacizumab naive recurrent grade IV gliomas</arm_group_label>
    <arm_group_label>Bevacuzumab exposed and refractive grade IV gliomas</arm_group_label>
    <arm_group_label>Bevacizumab naive recurrent grade III gliomas</arm_group_label>
    <arm_group_label>Bevacizumab exposed and refractive grade III gliomas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PRDR</intervention_name>
    <description>daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions</description>
    <arm_group_label>Bevacizumab naive recurrent grade IV gliomas</arm_group_label>
    <arm_group_label>Bevacuzumab exposed and refractive grade IV gliomas</arm_group_label>
    <arm_group_label>Bevacizumab naive recurrent grade III gliomas</arm_group_label>
    <arm_group_label>Bevacizumab exposed and refractive grade III gliomas</arm_group_label>
    <other_name>re-irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnose of a grade WHO grade III or IV glioma

          -  Recurrent disease based on combination of clinical, imaging or histologic
             confirmation

          -  Must have previously received radiation and temozolomide to treat their glioma

          -  Bevacizumab naive patients must be &gt; 6months post completion of initial radiation
             therapy

          -  Bevacizumab exposed patients must be &gt; 3months post completion of initial radiation
             therapy

          -  Age must be &gt;18years, KPS must be greater than 60

          -  Hematology, chemistry and a urinalysis  must meet protocol specified criteria

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  May not be on full dose anti-coagulation therapy, Low molecular weight heparin is ok

          -  Uncontrolled hypertension (&gt;140/90mmHg)

          -  Prior malignancy unless treated &gt;1 year prior to study and have been  without
             treatment and    disease free for 1 yr

          -  active second malignancy unless non-melanoma skin cancer or cervical cancer in situ
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Howard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. Ian Robins, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Trask, BS</last_name>
    <phone>608-263-9528</phone>
    <email>trask@humonc.wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nick Anger, BS</last_name>
    <phone>608-262-8649</phone>
    <email>anger@humonc.wisc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steve Howard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>H. Ian Robins, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 25, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>anaplastic glioma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
